Table of Contents

Global Whole Exome Sequencing Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate

1 Market Scope

• 1.1 Product Details and Introduction
  • 1.1.1 Agilent HaloPlex -Product Introduction and Major Manufacturers
  • 1.1.2 Agilent SureSelect -Product Introduction and Major Manufacturers
  • 1.1.3 Agilent SureSelect QXT -Product Introduction and Major Manufacturers
  • 1.1.4 Illumina TruSeq Exome -Product Introduction and Major Manufacturers
  • 1.1.5 Roche Nimblegen SeqCap -Product Introduction and Major Manufacturers
  • 1.1.6 MYcroarray MYbaits -Product Introduction and Major Manufacturers
• 1.2 Market Snapshot
  • 1.2.1 Major Companies Overview
  • 1.2.2 Market Concentration
  • 1.2.3 Six-Year Compound Annual Growth Rate (CAGR)

2 Global Whole Exome Sequencing Market Assessment, by Segmentation

• 2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
• 2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
• 2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)

3 Regional Market Analysis

• 3.1 China Whole Exome Sequencing Market
  • 3.1.1 Top Companies leading Whole Exome Sequencing Development in China (2015-2020)
  • 3.1.2 Sales Value of Major Company in China Market (2015-2020)
  • 3.1.3 China Whole Exome Sequencing Price (USD/Unit), by Type (2019-2020)
  • 3.1.4 Sales in China Market, by Type (2015-2026)
• 3.2 EU Whole Exome Sequencing Market
  • 3.2.1 Top Companies leading Whole Exome Sequencing Development in EU (2015-2020)
  • 3.2.2 Sales Value of Major Company in EU Market (2015-2020)
  • 3.2.3 EU Whole Exome Sequencing Price (USD/Unit), by Type (2019-2020)
  • 3.2.4 Sales in EU Market, by Type (2015-2026)
• 3.3 USA Whole Exome Sequencing Market
  • 3.3.1 Top Companies leading Whole Exome Sequencing Development in USA (2015-2020)
  • 3.3.2 Sales Value of Major Company in USA Market (2015-2020)
  • 3.3.3 USA Whole Exome Sequencing Price (USD/Unit), by Type (2019-2020)
  • 3.3.4 Sales in USA Market, by Type (2015-2026)
• 3.4 Japan Whole Exome Sequencing Market
  • 3.4.1 Top Companies leading Whole Exome Sequencing Development in Japan (2015-2020)
  • 3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
  • 3.4.3 Japan Whole Exome Sequencing Price (USD/Unit), by Type (2019-2020)
  • 3.4.4 Sales in Japan Market, by Type (2015-2026)
• 3.5 India Whole Exome Sequencing Market
  • 3.5.1 Top Companies leading Whole Exome Sequencing Development in India (2015-2020)
  • 3.5.2 Sales Value of Major Company in India Market (2015-2020)
  • 3.5.3 India Whole Exome Sequencing Price (USD/Unit), by Type (2019-2020)
  • 3.5.4 Sales in India Market, by Type (2015-2026)
• 3.6 Southeast Asia Whole Exome Sequencing Market
  • 3.6.1 Top Companies leading Whole Exome Sequencing Development in Southeast Asia (2015-2020)
  • 3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
  • 3.6.3 Southeast Asia Whole Exome Sequencing Price (USD/Unit), by Type (2019-2020)
  • 3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
• 3.7 South America Whole Exome Sequencing Market
  • 3.7.1 Top Companies leading Whole Exome Sequencing Development in South America (2015-2020)
  • 3.7.2 Sales Value of Major Company in South America Market (2015-2020)
  • 3.7.3 South America Whole Exome Sequencing Price (USD/Unit), by Type (2019-2020)
  • 3.7.4 Sales in South America Market, by Type (2015-2026)

4 Value Chain (Impact of COVID-19)

• 4.1 Whole Exome Sequencing Value Chain Analysis
  • 4.1.1 Upstream
  • 4.1.2 Downstream
• 4.2 COVID-19 Impact on Whole Exome Sequencing Industry
  • 4.2.1 Industrial Policy Issued Under the Epidemic Situation
• 4.3 Cost-Under the Epidemic Situation
  • 4.3.1 Cost of Raw Material
• 4.4 Channel Analysis
  • 4.4.1 Distribution Channel-Under the Epidemic Situation
  • 4.4.2 Distributors

5 Regional Market Forecast (2021-2026)

• 5.1 Global Whole Exome Sequencing Sales and Growth Rate (2021-2026)
• 5.2 Global Whole Exome Sequencing Sales Value and Growth Rate (2021-2026)

6 Whole Exome Sequencing Competitive Analysis

• 6.1 Illumina
  • 6.1.1 Illumina Company Profiles
  • 6.1.2 Illumina Product Introduction
  • 6.1.3 Illumina Whole Exome Sequencing Production, Revenue (2015-2020)
  • 6.1.4 SWOT Analysis
• 6.2 Thermo Fisher
  • 6.2.1 Thermo Fisher Company Profiles
  • 6.2.2 Thermo Fisher Product Introduction
  • 6.2.3 Thermo Fisher Whole Exome Sequencing Production, Revenue (2015-2020)
  • 6.2.4 SWOT Analysis
• 6.3 Roche
  • 6.3.1 Roche Company Profiles
  • 6.3.2 Roche Product Introduction
  • 6.3.3 Roche Whole Exome Sequencing Production, Revenue (2015-2020)
  • 6.3.4 SWOT Analysis
• 6.4 Angilent
  • 6.4.1 Angilent Company Profiles
  • 6.4.2 Angilent Product Introduction
  • 6.4.3 Angilent Whole Exome Sequencing Production, Revenue (2015-2020)
  • 6.4.4 SWOT Analysis
• 6.5 Eurofins
  • 6.5.1 Eurofins Company Profiles
  • 6.5.2 Eurofins Product Introduction
  • 6.5.3 Eurofins Whole Exome Sequencing Production, Revenue (2015-2020)
  • 6.5.4 SWOT Analysis
• 6.6 Sengenics
  • 6.6.1 Sengenics Company Profiles
  • 6.6.2 Sengenics Product Introduction
  • 6.6.3 Sengenics Whole Exome Sequencing Production, Revenue (2015-2020)
  • 6.6.4 SWOT Analysis
• 6.7 Ambry
  • 6.7.1 Ambry Company Profiles
  • 6.7.2 Ambry Product Introduction
  • 6.7.3 Ambry Whole Exome Sequencing Production, Revenue (2015-2020)
  • 6.7.4 SWOT Analysis
• 6.8 Macrogen
  • 6.8.1 Macrogen Company Profiles
  • 6.8.2 Macrogen Product Introduction
  • 6.8.3 Macrogen Whole Exome Sequencing Production, Revenue (2015-2020)
  • 6.8.4 SWOT Analysis
• 6.9 BGI
  • 6.9.1 BGI Company Profiles
  • 6.9.2 BGI Product Introduction
  • 6.9.3 BGI Whole Exome Sequencing Production, Revenue (2015-2020)
  • 6.9.4 SWOT Analysis
• 6.10 Novo Gene
  • 6.10.1 Novo Gene Company Profiles
  • 6.10.2 Novo Gene Product Introduction
  • 6.10.3 Novo Gene Whole Exome Sequencing Production, Revenue (2015-2020)
  • 6.10.4 SWOT Analysis

7 Conclusion

Summary

As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.

Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Whole Exome Sequencing market in this environment.

In terms of revenue, this research report indicated that the global Whole Exome Sequencing market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Whole Exome Sequencing industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.

The Illumina aims at producing XX Whole Exome Sequencing in 2020, with XX % production to take place in global market, Thermo Fisher accounts for a volume share of XX %.

Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Whole Exome Sequencing Market by XYZResearch Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Whole Exome Sequencing Market?
Illumina
Thermo Fisher
Roche
Angilent
Eurofins
Sengenics
Ambry
Macrogen
BGI
Novo Gene
...
Major Type of Whole Exome Sequencing Covered in XYZResearch report:
Agilent HaloPlex
Agilent SureSelect
Agilent SureSelect QXT
Illumina TruSeq Exome
Roche Nimblegen SeqCap
MYcroarray MYbaits
Application Segments Covered in XYZResearch Market
Correlation research of normal human
Mendelian disease and rare syndrome gene discovery
The research of complex diseases
Mouse exome sequencing
Other

For any other requirements, please feel free to contact us and we will provide you customized report.